- Home
- ANIX vs ATOS Comparison
ANIX vs ATOS Comparison
Compare ANIX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ATOS
- Stock Information
- Founded
- ANIX 1982
- ATOS 2009
- Country
- ANIX United States
- ATOS United States
- Employees
- ANIX N/A
- ATOS N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- ATOS Health Care
- Exchange
- ANIX Nasdaq
- ATOS Nasdaq
- Market Cap
- ANIX 84.7M
- ATOS 96.8M
- IPO Year
- ANIX 1987
- ATOS 2012
- Fundamental
- Price
- ANIX $2.63
- ATOS $0.81
- Analyst Decision
- ANIX Strong Buy
- ATOS Strong Buy
- Analyst Count
- ANIX 3
- ATOS 3
- Target Price
- ANIX $9.00
- ATOS $7.13
- AVG Volume (30 Days)
- ANIX 36.2K
- ATOS 620.7K
- Earning Date
- ANIX 06-03-2025
- ATOS 05-16-2025
- Dividend Yield
- ANIX N/A
- ATOS N/A
- EPS Growth
- ANIX N/A
- ATOS N/A
- EPS
- ANIX N/A
- ATOS N/A
- Revenue
- ANIX N/A
- ATOS N/A
- Revenue This Year
- ANIX N/A
- ATOS N/A
- Revenue Next Year
- ANIX N/A
- ATOS N/A
- P/E Ratio
- ANIX N/A
- ATOS N/A
- Revenue Growth
- ANIX N/A
- ATOS N/A
- 52 Week Low
- ANIX $2.07
- ATOS $0.55
- 52 Week High
- ANIX $4.20
- ATOS $1.81
- Technical
- Relative Strength Index (RSI)
- ANIX 42.93
- ATOS 56.67
- Support Level
- ANIX $2.70
- ATOS $0.59
- Resistance Level
- ANIX $2.84
- ATOS $0.92
- Average True Range (ATR)
- ANIX 0.16
- ATOS 0.07
- MACD
- ANIX -0.01
- ATOS 0.01
- Stochastic Oscillator
- ANIX 25.62
- ATOS 62.44
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.